VALN|Valneva SE|Price:9.490|Chg%:0.16

More Details of Valneva SE Company

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SE Info



Ticker SymbolVALN

Company nameValneva SE

IPO dateJun 28, 2007

CEOLingelbach (Thomas)

Number of employees- -

Security typeDepository Receipt

Fiscal year-endJun 28

Address6, Rue Alain Bombard

CitySAINT-HERBLAIN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryFrance

Postal code44800

Phone33228073710

Websitehttps://valneva.com/

Ticker SymbolVALN

IPO dateJun 28, 2007

CEOLingelbach (Thomas)

Company Executives of Valneva SE



Name

Name/Position

Position

Shareholding

Change

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Mr. Peter Buehler

Chief Financial Officer

--

Ms. Dipal Patel

Chief Commercial Officer

--

Mr. James Connolly

Independent Director

--

Ms. Mailys Ferrere

Director, Representative of Bpifrance Participations SA

--

Name

Name/Position

Position

Shareholding

Change

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

IXIARO

94.07M

55.47%

Third party products

33.19M

19.57%

DUKORAL

32.30M

19.05%

Chikungunya VLA1553

3.70M

2.18%

Others

1.13M

0.67%

Unallocated

704.00K

0.42%

By RegionUSD

Name

Revenue

Proportion

United States

48.59M

28.66%

Canada

32.32M

19.06%

United Kingdom

19.49M

11.49%

Germany

18.37M

10.84%

Austria

15.90M

9.37%

Other

34.91M

20.58%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

IXIARO

94.07M

55.47%

Third party products

33.19M

19.57%

DUKORAL

32.30M

19.05%

Chikungunya VLA1553

3.70M

2.18%

Others

1.13M

0.67%

Unallocated

704.00K

0.42%

Shareholding Stats

Updated: 4 hours ago

Shareholders

Shareholder Types

Shareholders

Proportion

Novo Holdings A/S

2.73%

Frazier Life Sciences Management, L.P.

2.67%

General American Investors Company, Inc.

0.41%

Wells Fargo Advisors

0.18%

Marshall Wace LLP

0.04%

Other

93.97%

Shareholders

Proportion

Novo Holdings A/S

2.73%

Frazier Life Sciences Management, L.P.

2.67%

General American Investors Company, Inc.

0.41%

Wells Fargo Advisors

0.18%

Marshall Wace LLP

0.04%

Other

93.97%

Shareholder Types

Shareholders

Proportion

Venture Capital

2.73%

Private Equity

2.67%

Investment Advisor

0.46%

Research Firm

0.22%

Investment Advisor/Hedge Fund

0.04%

Hedge Fund

0.02%

Other

93.86%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

32

5.28M

6.15%

+519.56K

2025Q3

30

4.53M

5.58%

+3.61M

2025Q2

25

665.50K

0.82%

-300.83K

2025Q1

28

666.20K

0.82%

-333.59K

2024Q4

27

820.97K

1.18%

-47.15K

2024Q3

26

836.06K

1.21%

+31.78K

2024Q2

28

742.08K

1.07%

+162.52K

2024Q1

32

513.10K

0.74%

-47.53K

2023Q4

30

421.64K

0.61%

-110.65K

2023Q3

32

418.35K

0.60%

-285.66K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Novo Holdings A/S

2.35M

2.73%

-30.00K

-1.26%

Sep 30, 2025

Frazier Life Sciences Management, L.P.

2.29M

2.67%

+833.33K

+57.14%

Sep 30, 2025

General American Investors Company, Inc.

354.36K

0.41%

--

Sep 30, 2025

Wells Fargo Advisors

153.99K

0.18%

-91.19K

-37.19%

Sep 30, 2025

Marshall Wace LLP

31.21K

0.04%

+31.21K

--

Sep 30, 2025

Ironwood Investment Management, LLC

25.14K

0.03%

--

Sep 30, 2025

Morgan Stanley & Co. International Plc

22.77K

0.03%

+16.23K

+248.03%

Sep 30, 2025

Citadel Advisors LLC

16.41K

0.02%

-19.33K

-54.08%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

10.20K

0.01%

+8.72K

+589.93%

Sep 30, 2025

J.P. Morgan Securities LLC

10.18K

0.01%

+10.18K

--

Sep 30, 2025

Related ETFs



Name

Proportion

No Data

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data